Technology
Health
Pharmaceutical

Aratana Therapeutics

$4.74
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-0.83%) Today
-$0.02 (-0.53%) After Hours

Why Robinhood?

You can buy or sell PETX and other stocks, options, ETFs, and crypto commission-free!

About

Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. Read More NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS.

Employees
83
Headquarters
Leawood, Kansas
Founded
2010
Market Cap
229.52M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
548.24K
High Today
$4.82
Low Today
$4.71
Open Price
$4.82
Volume
83.42K
52 Week High
$7.16
52 Week Low
$3.30

Collections

Technology
Health
Pharmaceutical
Therapy
Dogs
Cats
2013 IPO
US

News

Yahoo FinanceMay 9

PETX, KEYW, and ZAYO SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

WILMINGTON, Del., May 09, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: Aratana Therapeutics, Inc. (NASDAQ GM: PETX ) regarding possible breaches of fiduciary duties and other violations of law related to Aratana’s agreement to be acquired by Elanco Animal Health Incorporated. Shareholders of Aratana will receive for 0.1481 shares of Elanco per share of Aratana. To learn more about this investigation and your rights, visit: https://www.rigrodskylong.com/cases-aratana...

138
Yahoo FinanceMay 8

Aratana (PETX) Reports Q1 Loss, Tops Revenue Estimates

CCA (CXW) delivered FFO and revenue surprises of 8.47% and 3.71%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

35
Yahoo FinanceMay 2

MERGER ALERT - PETX, BRSS and KEYW: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies

NEW YORK, NY / ACCESSWIRE / May 2, 2019 / The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Aratana Therapeutics, Inc. (PETX) Merger Announcement: April 26, 2019 Transaction Details: Under the terms of the transaction, Aratana shareholders will receive 0.1481 shares of Elanco Animal Health Incorporated (NYSE:ELAN) common stock and a contingent value rig...

229

Earnings

-$0.25
-$0.10
$0.04
$0.19
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.